Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) — Telix Prescription drugs Restricted (ASX: TLX, NASDAQ: TLX, “Telix”) at the moment pronounces an academic webinar exploring the unmet wants in neurologic oncology (particularly glioma and glioblastoma) and how theranostics might assist handle these.

David N. Cade, MD, Telix Group Chief Medical Officer will present a scientific replace, which will likely be adopted by a hearth chat with Nelleke Tolboom, MD, Nuclear Medication doctor and tutorial college member at UMC Utrecht (Netherlands) and Josef Pichler, MD, Head of the Neuro-oncological Heart at Kepler College Hospital Linz (Austria).

The presentation will likely be adopted by Q&A with Dr. Cade and Richard Valeix, CEO, Telix Therapeutics.

Webinar date and time:

EDT: Monday June 29, 2026, 5:00 p.m.

AEST: Tuesday June 30, 2026, 7:00 a.m.

Individuals can register for the webinar on the following hyperlink:
https://s1.c-conf.com/diamondpass/10054826-mur5i9.html

About Telix Prescription drugs Restricted

Telix is a worldwide biopharmaceutical firm centered on the event and commercialization of radiopharmaceuticals with the purpose of addressing vital unmet medical want in oncology and uncommon illnesses. Telix is headquartered in Melbourne (Australia) with worldwide operations in the US, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Change (ASX: TLX) and the Nasdaq International Choose Market (NASDAQ: TLX).

Go to www.telixpharma.com for additional details about Telix, together with particulars of the most recent share value, ASX and U.S. Securities and Change Fee (SEC) filings, investor and analyst displays, information releases, occasion particulars and different publications which may be of curiosity. You too can comply with Telix on LinkedIn, X and Fb.

Authorized Notices

Cautionary Assertion Concerning Ahead-Trying Statements. 

You need to learn this announcement along with our threat elements, as disclosed in our most not too long ago filed experiences with the Australian Securities Change (ASX), U.S. Securities and Change Fee (SEC), together with our Annual Report on Type 20-F filed with the SEC, or on our web site.

The data contained on this announcement will not be supposed to be a proposal for subscription, invitation or advice with respect to securities of Telix Prescription drugs Restricted (Telix) in any jurisdiction, together with the US. The data and opinions contained on this announcement are topic to vary with out notification.  To the utmost extent permitted by legislation, Telix disclaims any obligation or enterprise to replace or revise any info or opinions contained on this announcement, together with any forward-looking statements (as referred to under), whether or not on account of new info, future developments, a change in expectations or assumptions, or in any other case. No illustration or guarantee, categorical or implied, is made in relation to the accuracy or completeness of the knowledge contained or opinions expressed in the midst of this announcement.

This announcement might include forward-looking statements, together with inside the which means of the U.S. Non-public Securities Litigation Reform Act of 1995, that relate to anticipated future occasions, monetary efficiency, plans, methods or enterprise developments. Ahead-looking statements can usually be recognized by means of phrases comparable to “might”, “count on”, “intend”, “plan”, “estimate”, “anticipate”, “consider”, “outlook”, “forecast” and “steering”, or the destructive of those phrases or different comparable phrases or expressions. Ahead-looking statements contain identified and unknown dangers, uncertainties and different elements that will trigger our precise outcomes, ranges of exercise, efficiency or achievements to vary materially from any future outcomes, ranges of exercise, efficiency or achievements expressed or implied by these forward-looking statements. Ahead-looking statements are primarily based on Telix’s good-faith assumptions as to the monetary, market, regulatory and different dangers and issues that exist and have an effect on Telix’s enterprise and operations sooner or later and there may be no assurance that any of the assumptions will show to be appropriate. Within the context of Telix’s enterprise, forward-looking statements might embrace, however aren’t restricted to, statements about: the initiation, timing, progress, completion and outcomes of Telix’s preclinical and scientific trials, and Telix’s analysis and growth packages; Telix’s capability to advance product candidates into, enroll and efficiently full, scientific research, together with multi-national scientific trials; the timing or probability of regulatory filings and approvals for Telix’s product candidates, manufacturing actions and product advertising and marketing actions; Telix’s gross sales, advertising and marketing and distribution and manufacturing capabilities and methods; the commercialization of Telix’s product candidates, if or after they have been authorized; Telix’s capability to acquire an ample provide of uncooked supplies at affordable prices for its merchandise and product candidates; estimates of Telix’s bills, future revenues and capital necessities; Telix’s monetary efficiency; developments regarding Telix’s opponents and business; the anticipated influence of U.S. and overseas tariffs and different macroeconomic circumstances on Telix’s enterprise, together with on account of battle or different geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they’ve been authorized. Telix’s precise outcomes, efficiency or achievements could also be materially totally different from these which can be expressed or implied by such statements, and the variations could also be adversarial. Accordingly, you shouldn’t place undue reliance on these forward-looking statements.

Logos and Commerce Names. All logos and commerce names referenced on this press launch are the property of Telix Prescription drugs Restricted (Telix) or, the place relevant, the property of their respective house owners. For comfort, logos and commerce names might seem with out the ® or ™ symbols. Such omissions aren’t supposed to point any waiver of rights by Telix or the respective house owners. Trademark registration standing might fluctuate from nation to nation. Telix doesn’t intend the use or show of any third-party logos or commerce names to indicate any affiliation with, endorsement by, or sponsorship from these third events.

©2026 Telix Prescription drugs Restricted. All rights reserved.